A small-molecule inhibitor of Keap1–Nrf2 interaction attenuates sepsis by selectively augmenting the antibacterial defence of macrophages at infection sites
Yawei Wang,Binlin Tang,Huijuan Li,Jiancheng Zheng,Can Zhang,Zeyu Yang,Xu Tan,Peng Luo,Le Ma,Yang Wang,Lei Long,Zelin Chen,Zhenliang Xiao,Lijie Ma,Jing Zhou,Yu Wang,Chunmeng Shi
DOI: https://doi.org/10.1016/j.ebiom.2023.104480
IF: 11.205
2023-03-02
EBioMedicine
Abstract:Summary Background Macrophages at infection sites are considered as the promising therapeutic targets to prevent sepsis development. The Nrf2/Keap1 system acts as a critical modulator of the antibacterial activity of macrophages. Recently, Keap1–Nrf2 protein–protein interaction (PPI) inhibitors have emerged as safer and stronger Nrf2 activators; however, their therapeutic potential in sepsis remains unclear. Herein, we report a unique heptamethine dye, IR-61, as a Keap1–Nrf2 PPI inhibitor that preferentially accumulates in macrophages at infection sites. Methods A mouse model of acute lung bacterial infection was used to investigate the biodistribution of IR-61. SPR study and CESTA were used to detect the Keap1 binding behaviour of IR-61 in vitro and in cells. Established models of sepsis in mice were used to determine the therapeutic effect of IR-61. The relationship between Nrf2 levels and sepsis outcomes was preliminarily investigated using monocytes from human patients. Findings Our data showed that IR-61 preferentially accumulated in macrophages at infection sites, enhanced bacterial clearance, and improved outcomes in mice with sepsis. Mechanistic studies indicated that IR-61 potentiated the antibacterial function of macrophages by activating Nrf2 via direct inhibition of the Keap1–Nrf2 interaction. Moreover, we observed that IR-61 enhanced the phagocytic ability of human macrophages, and the expression levels of Nrf2 in monocytes might be associated with the outcomes of sepsis patients. Interpretations Our study demonstrates that the specific activation of Nrf2 in macrophages at infection sites is valuable for sepsis management. IR-61 may prove to be a Keap1-Nrf2 PPI inhibitor for the precise treatment of sepsis. Funding This work was supported by the National Natural Science Foundation of China (Major program 82192884 ), the Intramural Research Project (Grants: 2018-JCJQ-ZQ-001 and 20QNPY018 ), and the Chongqing National Science Foundation ( CSTB2022NSCQ-MSX1222 ).
medicine, research & experimental